248 related articles for article (PubMed ID: 32712168)
1. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.
Heybeli C; Bentall A; Wen J; Alexander MP; Buadi FK; Cosio FG; Dean PG; Dispenzieri A; Dingli D; El Ters M; Gertz MA; Hatem A; Kapoor P; Khamash H; Kourelis T; Kumar S; Lorenz EC; Mai M; Muchtar E; Murray DL; Prieto M; Schinstock CA; Stegall MD; Warsame R; Leung N
Kidney Int; 2021 Mar; 99(3):707-715. PubMed ID: 32712168
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
Havasi A; Heybeli C; Leung N; Angel-Korman A; Sanchorawala V; Cohen O; Wechalekar A; Bridoux F; Jaffer I; Gutgarts V; Hassoun H; Levinson M; Rosenbaum C; Milani P; Palladini G; Merlini G; Hegenbart U; Schönland S; Veelken K; Pogrebinsky A; Doros G; Landau H
Blood Cancer J; 2022 Aug; 12(8):119. PubMed ID: 35982035
[TBL] [Abstract][Full Text] [Related]
3. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
4. How I Approach Light Chain Amyloidosis.
Chowdhury RB; Leung N
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007836
[TBL] [Abstract][Full Text] [Related]
5. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
Herrmann SM; Gertz MA; Stegall MD; Dispenzieri A; Cosio FC; Kumar S; Lacy MQ; Dean PG; Prieto M; Zeldenrust SR; Buadi FK; Russell SJ; Nyberg SL; Hayman SR; Dingli D; Fervenza FC; Leung N
Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
8. Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis.
Al Saleh AS; Sidiqi MH; Sidana S; Muchtar E; Dispenzieri A; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Wolf RC; Kapoor P; Buadi FK; Kumar SK; Gertz MA
Am J Hematol; 2019 Oct; 94(10):1066-1071. PubMed ID: 31273808
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of kidney transplantation in AL amyloidosis.
Angel-Korman A; Stern L; Sarosiek S; Sloan JM; Doros G; Sanchorawala V; Havasi A
Kidney Int; 2019 Feb; 95(2):405-411. PubMed ID: 30580886
[TBL] [Abstract][Full Text] [Related]
10. Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.
Sidiqi MH; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Mar; 25(3):e108-e111. PubMed ID: 30529461
[TBL] [Abstract][Full Text] [Related]
11. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
12. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
13. Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series.
Heybeli C; Alexander MP; Bentall AJ; Amer H; Buadi FK; Dean PG; Dingli D; Dispenzieri A; El Ters M; Gertz MA; Issa NS; Kapoor P; Kourelis T; Kukla A; Kumar S; Lacy MQ; Lorenz EC; Muchtar E; Murray DL; Nasr SH; Prieto M; Rajkumar SV; Schinstock CA; Stegall MD; Warsame R; Leung N
Am J Kidney Dis; 2022 Feb; 79(2):202-216. PubMed ID: 34175375
[TBL] [Abstract][Full Text] [Related]
14. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis.
Sidiqi MH; Aljama MA; Jevremovic D; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz MA
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2360-2364. PubMed ID: 29964192
[TBL] [Abstract][Full Text] [Related]
16. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
Jain T; Kosiorek HE; Kung ST; Shah VS; Dueck AC; Gonzalez-Calle V; Luft S; Reeder CB; Adams R; Noel P; Larsen JT; Mikhael J; Bergsagel L; Stewart AK; Fonseca R
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):486-492.e1. PubMed ID: 29753692
[TBL] [Abstract][Full Text] [Related]
17. Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: The Mayo Clinic experience.
Grogan M; Gertz M; McCurdy A; Roeker L; Kyle R; Kushwaha S; Daly R; Dearani J; Rodeheffer R; Frantz R; Lacy M; Hayman S; McGregor C; Edwards B; Dispenzieri A
World J Transplant; 2016 Jun; 6(2):380-8. PubMed ID: 27358783
[TBL] [Abstract][Full Text] [Related]
18. Renal transplant outcomes in amyloidosis.
Law S; Cohen O; Lachmann HJ; Rezk T; Gilbertson JA; Rowczenio D; Wechalekar AD; Hawkins PN; Motallebzadeh R; Gillmore JD
Nephrol Dial Transplant; 2021 Jan; 36(2):355-365. PubMed ID: 33439995
[TBL] [Abstract][Full Text] [Related]
19. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
